NCT03554005View on ClinicalTrials.gov

Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 29, 1997

Primary Completion Date

March 16, 2001

Study Completion Date

March 16, 2001

Conditions
Neoplasms
Interventions
DRUG

PEG Interferon Alfa-2b

Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.

DRUG

Acetaminophen

Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03554005 - Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009) | Biotech Hunter | Biotech Hunter